Trends and emerging technologies in extracorporeal life support: results of the 2006 ECLS survey.

Extracorporeal life support (ECLS) is a procedure used to support the failing heart and/or lungs via a heart lung machine. Over 145 institutions perform this practice in the United States with more than 24,000 ECLS cases recorded. While many articles are published each year on common perfusion practice, little information is shared on emerging technologies in ECLS and common practices among perfusionists and ECLS specialists. This article presents our 2006 ECLS survey results and discusses emerging technologies and management topics new to the ECLS arena. ECLS specialists were asked to participate in an online survey. Two hundred twenty-two ECLS specialists responded. This survey suggests positive displacement roller pumps are still the leading pump used for ECLS 122/188 (64.9%). Silicone membrane oxygenators are used by responders 75% of the time for long-term use, while hollow fiber membrane oxygenators are used 44%. Forty-five percent of responders are using heparin or biocoated circuits exclusively, while 14.6% restrict their use to specific subpopulations. The most common coating is heparin coating (67.9%). Activated clotting time (ACT) management is still standard of care for coagulation monitoring (98%), while partial thromboplastin time (PTT) follows at 71.7%. The interquartile range for ACTs is 160-220 seconds and 160-200 seconds with active bleeding. This article suggests ECLS specialists are beginning to incorporate different technology into their practice, such as centrifugal pumps with hollow fiber oxygenators and coated-circuits.

[1]  F. Pigula,et al.  Anticoagulation and pediatric extracorporeal membrane oxygenation: impact of activated clotting time and heparin dose on survival. , 2007, The Annals of thoracic surgery.

[2]  T. Nakatani,et al.  Early Experience with Low-Prime (99 ml) Extracorporeal Membrane Oxygenation Support in Children , 2006, ASAIO journal.

[3]  B. Searles,et al.  2004 survey of ECMO in the neonate after open heart surgery: circuitry and team roles. , 2005, The journal of extra-corporeal technology.

[4]  A. Ündar,et al.  Pulsatile ECMO in Neonates and Infants: First European Clinical Experience with a New Device , 2005, ASAIO journal.

[5]  A. Sosnowski,et al.  Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators , 2005, Perfusion.

[6]  E. Tatsumi,et al.  PROLONGED HEPARINLESS ANIMAL TESTING OF A NEWLY DEVELOPED ANTITHROMBOGENIC HEPARIN-COATED PEDIATRIC ECMO SYSTEM , 2005 .

[7]  S. Suehiro,et al.  A new poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit possesses superior platelet preservation and inflammatory suppression efficacy. , 2004, The Annals of thoracic surgery.

[8]  John D Lambris,et al.  Effect of complement inhibition and heparin coating on artificial surface-induced leukocyte and platelet activation. , 2004, The Annals of thoracic surgery.

[9]  J. Jaggers,et al.  North American neonatal extracorporeal membrane oxygenation (ECMO) devices: 2002 survey results. , 2004, The journal of extra-corporeal technology.

[10]  C. Brizard,et al.  Experience with the Jostra Rotaflow and QuadroxD oxygenator for ECMO , 2004, Perfusion.

[11]  P. Wolfson.  The development and use of extracorporeal membrane oxygenation in neonates. , 2003, The Annals of thoracic surgery.

[12]  R. Bartlett,et al.  Thrombogenicity Is Not Reduced When Heparin and Phospholipid Bonded Circuits Are Used in a Rabbit Model of Extracorporeal Circulation , 2003, ASAIO journal.

[13]  C. Parvin,et al.  Evaluation of the TAS analyzer and the low-range heparin management test in patients undergoing extracorporeal membrane oxygenation. , 2001, Clinical chemistry.

[14]  C. Ludlam,et al.  Individualized heparin and protamine management in infants and children undergoing cardiac operations. , 2001, The Annals of thoracic surgery.

[15]  J. Owings,et al.  Anticoagulation of children undergoing cardiopulmonary bypass is overestimated by current monitoring techniques. , 2000, Archives of surgery.

[16]  H. Akashi,et al.  Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. , 2000, Artificial organs.

[17]  R. Hetzer,et al.  Prevalence and persistence of heparin/platelet factor 4 antibodies in patients with heparin coated and noncoated ventricular assist devices. , 2000, ASAIO journal.

[18]  J. Jaggers,et al.  Infant cardiopulmonary bypass: a procoagulant state. , 1999, The Annals of thoracic surgery.

[19]  P. D. del Nido,et al.  Use of rapid-deployment extracorporeal membrane oxygenation for the resuscitation of pediatric patients with heart disease after cardiac arrest. , 1998, The Journal of thoracic and cardiovascular surgery.

[20]  E. Spitznagel,et al.  The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. , 1995, The Journal of thoracic and cardiovascular surgery.

[21]  M. Acker,et al.  Intracardiac thrombus: a risk of incomplete anticoagulation for cardiac operations. , 1994, The Annals of thoracic surgery.

[22]  J. L. Rodriguez,et al.  Early experience with adult extracorporeal membrane oxygenation in the modern era. , 1992, The Annals of thoracic surgery.

[23]  J. Zwischenberger,et al.  Devices and monitoring during neonatal ECMO: su rvey results , 1990, Perfusion.

[24]  R. Bartlett,et al.  Extracorporeal Membrane Oxygenation (ECMO) in Neonatal Respiratory Failure , 1986 .

[25]  R. Bartlett.  Extracorporeal oxygenation in neonates. , 1984, Hospital practice.

[26]  R. Bartlett,et al.  Extracorporeal membrane oxygenation (ECMO) cardiopulmonary support in infancy. , 1979, Transactions - American Society for Artificial Internal Organs.

[27]  B. Bull,et al.  Heparin therapy during extracorporeal circulation. II. The use of a dose-response curve to individualize heparin and protamine dosage. , 1975, The Journal of thoracic and cardiovascular surgery.

[28]  J J Osborn,et al.  Prolonged extracorporeal oxygenation for acute post-traumatic respiratory failure (shock-lung syndrome). Use of the Bramson membrane lung. , 1972, The New England journal of medicine.

[29]  T. Igari,et al.  Changes in platelet aggregation during cardiopulmonary bypass: comparison of poly-2-methoxyethylacrylate and heparin as a circuit coating material , 2004, Journal of Artificial Organs.

[30]  E. Fosse,et al.  Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass. , 1997, The Annals of thoracic surgery.

[31]  R. Bartlett,et al.  Extracorporeal life support for adult cardiorespiratory failure. , 1993, Surgery.